Latest pharmaceutical industry Stories
CUPERTINO, Calif., May 2, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31, 2013. For comparison, total GAAP revenue was $41.2 million and net income was $30.8 million for the three months ended March 31, 2012. The revenue for the first quarter of 2012 included the accelerated recognition of $35.4 million in...
-- Conference Call and Webcast Scheduled for Today at 5:15 p.m. Eastern Time -- SAN DIEGO, May 2, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2013. Recent Developments: BELVIQ(® )(lorcaserin HCl) The American Association of Clinical Endocrinologists (AACE) published its Comprehensive Diabetes Management Algorithm. This document provides treatment...
ELAGOLIX ENTERS PHASE IIB FOR UTERINE FIBROIDS, ENDOMETRIOSIS PHASE III PROGRAM ON TRACK SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2013. For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a net loss of $0.9 million, or $0.01 loss per share, for the same period in 2012. This $11.2 million change in operating...
INDIANAPOLIS, May 2, 2013 /PRNewswire/ -- Vertellus Specialties Inc. announces that its facility in Antwerp, Belgium has completed capital and other upgrades for the manufacture of Niacin (nicotinic acid) for pharmaceutical use. The plant has been producing Niacin USP and Niacinamide for nearly 30 years and has reliably supplied the ingredient for human food applications as well as agricultural needs. Vertellus completed projects over the last year to upgrade the facility to meet...
GERMANTOWN, Md., May 2, 2013 /PRNewswire/ -- RNL BIO, a stem cell biotechnology company dedicated to the commercialization of autologous cell therapy products for a variety of degenerative, ischemic and other indications, has announced that it has filed an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) to begin clinical trials with its adipose-derived stem cell product, termed RNL-JointStem, for the treatment of osteoarthritis (OA). Assuming...
2013 Q1 NME FDA approvals indicates drug names are trending to longer lengths, more syllables and greater distinction. NEW YORK, May 2, 2013 /PRNewswire-iReach/ -- For the first quarter of the 2013 calendar year, the FDA's Center for Drug Evaluation and Research (CDER) has approved nine new molecular entities. A total of 39 novel new medicines were approved in 2012, the highest total in sixteen years. Our conclusions are based on a comparison of the average number of letters and...
- CRO exhibiting and speaking at Outsourcing in Clinical Trials Southeast and Outsourcing in Clinical Trials in Europe - SAN DIEGO, May 2, 2013 /PRNewswire/ -- SynteractHCR, a full-service, global contract research organization (CRO), will attend and present at two conferences in May, Outsourcing in Clinical Trials Southeast and Outsourcing in Clinical Trials Europe. Speakers Barbara Ruby and Dr. Sonja Weiser will address the relationship between sponsors and outsourced clinical...
Competition from generics, pricing pressures, and decreasing healthcare spending ripples the market MOUNTAIN VIEW, Calif., May 2, 2013 /PRNewswire/ -- In the face of reduced profit margins for the pharmaceutical and biotechnology sectors, an effective financial management strategy is central to maintain sustainable growth. New analysis from Frost & Sullivan's (http://www.financialservices.frost.com) Financial Assessment of the Global Pharmaceutical and Biotechnology Industry...
NEW YORK, May 2, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of Thomas M. Riedhammer, Ph.D., to its Board of Directors. Dr. Riedhammer has over 35 years of ophthalmic industry experience, working for large and small pharmaceutical companies engaged in drug development through commercialization. "We are pleased to have brought on someone...
Growth platforms(2) sales increased 8.6%(3) PARIS, May 2, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2013 Change (reported) Change (CER) Net sales EUR8,059m -5.3% -2.8% Business net income(1) EUR1,613m -33.5% -28.8% Business EPS(1) EUR1.22 -33.3% -29.0% In order to facilitate an understanding of our...
